These findings demonstrate that Idelalisib targets multiple mechanisms of CLL cell survival by not only direct inhibition of the PI3K signaling pathway but also by inhibition of extrinsic activation of this pathway by microenvironmental stimuli from CD40L, BAFF, TNF-α, and fibronectin. This evidence concerns the gene PIK3CD and B-cell chronic lymphocytic leukemia.